1
|
Hsueh WY, Lee YSE, Huang MS, Lai CH, Gao YS, Lin JC, Chen YF, Chang CL, Chou SY, Chen SF, Lu YY, Chang LH, Lin SF, Lin YH, Hsu PC, Wei WY, Huang YC, Kao YF, Teng LW, Liu HH, Chen YC, Yuan TT, Chan YW, Huang PH, Chao YT, Huang SY, Jian BH, Huang HY, Yang SC, Lo TH, Huang GR, Wang SY, Lin HS, Chuang SH, Huang JJ. Copper(I)-Catalyzed Nitrile-Addition/ N-Arylation Ring-Closure Cascade: Synthesis of 5,11-Dihydro-6 H-indolo[3,2- c]quinolin-6-ones as Potent Topoisomerase-I Inhibitors. J Med Chem 2021; 64:1435-1453. [PMID: 33492141 DOI: 10.1021/acs.jmedchem.0c00727] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
In this paper, we present a copper(I)-catalyzed nitrile-addition/N-arylation ring-closure cascade for the synthesis of 5,11-dihydro-6H-indolo[3,2-c]quinolin-6-ones from 2-(2-bromophenyl)-N-(2-cyanophenyl)acetamides. Using CuBr and t-BuONa in dimethylformamide (DMF) as the optimal reaction conditions, the cascade reaction gave the target products, in high yields, with a good substrate scope. Application of the cascade reaction was demonstrated on the concise total syntheses of alkaloid isocryptolepine. Further optimization of the products from the cascade reaction led to 3-chloro-5,12-bis[2-(dimethylamino)ethyl]-5,12-dihydro-6H-[1,3]dioxolo[4',5':5,6]indolo[3,2-c]quinolin-6-one (2k), which exhibited the characteristic DNA topoisomerase-I inhibitory mechanism of action with potent in vitro anticancer activity. Compound 2k actively inhibited ARC-111- and SN-38-resistant HCT-116 cells and showed in vivo activity in mice bearing human HCT-116 and SJCRH30 xenografts. The interaction of 2k with the Top-DNA cleavable complex was revealed by docking simulations to guide the future optimization of 5,11-dihydro-6H-indolo[3,2-c]quinolin-6-ones as topoisomerase-I inhibitors.
Collapse
Affiliation(s)
- Wen-Yun Hsueh
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Ying-Shuan E Lee
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Min-Sian Huang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Chin-Hung Lai
- Department of Applied Chemistry, Chung Shan Medical University, Taichung 40201, Taiwan
| | - Yu-Sheng Gao
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Jo-Chu Lin
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Yu-Fen Chen
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Chih-Lin Chang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Shan-Yen Chou
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Shyh-Fong Chen
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Yann-Yu Lu
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Lien-Hsiang Chang
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Shu Fu Lin
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Yu-Hsiang Lin
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Pi-Chen Hsu
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Win-Yin Wei
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Ya-Chi Huang
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Yi-Feng Kao
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Li-Wei Teng
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Hung-Huang Liu
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Ying-Chou Chen
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Ta-Tung Yuan
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Ya-Wen Chan
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Po-Hsun Huang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Yu-Ting Chao
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Shin-Yi Huang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Bo-Han Jian
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Hsin-Yi Huang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Sheng-Chuan Yang
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Tzu-Hao Lo
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Guan-Ru Huang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Shao-Yun Wang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan
| | - Her-Sheng Lin
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Shih-Hsien Chuang
- Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| | - Jiann-Jyh Huang
- Department of Applied Chemistry, National Chiayi University, No. 300, Syuefu Road, Chiayi City 60004, Taiwan.,Development Center for Biotechnology, National Biotechnology Research Park, Taipei City 11571, Taiwan
| |
Collapse
|
2
|
Meng H, Jiang X, Cui J, Yin G, Shi B, Liu Q, Xuan H, Wang Y. Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma. BIOMED RESEARCH INTERNATIONAL 2020; 2020:2495157. [PMID: 33062672 PMCID: PMC7545427 DOI: 10.1155/2020/2495157] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 07/03/2020] [Accepted: 08/17/2020] [Indexed: 02/07/2023]
Abstract
Clear cell renal cell carcinoma (ccRCC) accounts for more than 75% of renal cell carcinoma. Nearly 25% of ccRCC patients were diagnosed with metastasis. Though the genomic profile of ccRCC has been widely studied, the difference between localized and metastatic ccRCC was not clarified. Primary tumor samples and matched whole blood were collected from 106 sporadic patients diagnosed with renal clear cell carcinoma at Qilu Hospital of Shandong University from January 2017 to November 2019, and 17 of them were diagnosed with metastasis. A hybridization capture-based next-generation sequencing of 618 cancer-related genes was performed to investigate the somatic and germline variants, tumor mutation burden (TMB), and microsatellite instability (MSI). Five genes with significantly different prevalence were identified in the metastatic group, especially TOP1 (17.65% vs. 0%) and SNCAIP (17.65% vs. 0%). The altered frequency of PBRM1 (0% vs. 27%) and BAP1 (24% vs. 10%) differed between the metastatic and nonmetastatic groups, which may relate to the prognosis. Of these 106 patients, 42 patients (39.62%) had at least one alteration in DNA damage repair (DDR) genes, including 58.82% of metastatic ccRCC patients and 35.96% of ccRCC patients without metastasis. Ten pathogenic or likely pathogenic (P/LP) variants were identified in 11 sporadic clear cell renal cell carcinoma patients (10.38%), including rarely reported ATM (n=1), MUTYH (n=1), NBN (n=1), RAD51D (n=1), and BRCA2 (n=1). No significant difference in the ratio of P/LP variant carriers or TMB was identified between the metastatic and nonmetastatic groups. We found a unique genomic feature of Chinese metastatic ccRCC patients with a higher prevalence of alterations in DDR, TOP1, and SNCAIP. Further investigated studies and drug development are needed in the future.
Collapse
Affiliation(s)
- Hui Meng
- Department of Urology, Qilu Hospital of Shandong University, 107 Jinan Culture Road, Jinan, 250012 Shandong, China
| | - Xuewen Jiang
- Department of Urology, Qilu Hospital of Shandong University, 107 Jinan Culture Road, Jinan, 250012 Shandong, China
| | - Jianfeng Cui
- Department of Urology, Qilu Hospital of Shandong University, 107 Jinan Culture Road, Jinan, 250012 Shandong, China
| | - Gang Yin
- Department of Urology, Qilu Hospital of Shandong University, 107 Jinan Culture Road, Jinan, 250012 Shandong, China
| | - Benkang Shi
- Department of Urology, Qilu Hospital of Shandong University, 107 Jinan Culture Road, Jinan, 250012 Shandong, China
| | - Qi Liu
- Life Healthcare Medical Laboratory Co., Ltd., Hangzhou, 310052 Zhejiang, China
| | - He Xuan
- Life Healthcare Medical Laboratory Co., Ltd., Hangzhou, 310052 Zhejiang, China
| | - Yu Wang
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Jinan Culture Road, Jinan, 250012 Shandong, China
| |
Collapse
|
3
|
Song M, Yin S, Zhao R, Liu K, Kundu JK, Shim JH, Lee MH, Dong Z. (S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous Cell Carcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I Enzyme Activity. Cancers (Basel) 2019; 11:cancers11121964. [PMID: 31817790 PMCID: PMC6966462 DOI: 10.3390/cancers11121964] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Revised: 12/03/2019] [Accepted: 12/04/2019] [Indexed: 12/27/2022] Open
Abstract
Topoisomerase (TOP) I plays a major role in the process of supercoiled DNA relaxation, thereby facilitating DNA replication and cell cycle progression. The expression and enzymatic activity of TOP I is positively correlated with tumor progression. Although the anticancer activity of (S)-10-Hydroxycamptothecin (HCPT), a TOP I specific inhibitor, has been reported in various cancers, the effect of HCPT on esophageal cancer is yet to be examined. In this study, we investigate the potential of HCPT to inhibit the growth of ESCC cells in vitro and verify its anti-tumor activity in vivo by using a patient-derived xenograft (PDX) tumor model in mice. Our study revealed the overexpression of TOP I in ESCC cells and treatment with HCPT inhibited TOP I enzymatic activity at 24 h and decreased expression at 48 h and 72 h. HCPT also induced DNA damage by increasing the expression of H2A.XS139. HCPT significantly decreased the proliferation and anchorage-independent growth of ESCC cells (KYSE410, KYSE510, KYSE30, and KYSE450). Mechanistically, HCPT inhibited the G2/M phase cell cycle transition, decreased the expression of cyclin B1, and elevated p21 expression. In addition, HCPT stimulated ESCC cells apoptosis, which was associated with elevated expression of cleaved PARP, cleaved caspase-3, cleaved caspase-7, Bax, Bim, and inhibition of Bcl-2 expression. HCPT dramatically suppressed PDX tumor growth and decreased the expression of Ki-67 and TOP I and increased the level of cleaved caspase-3 and H2A.XS139 expression. Taken together, our data suggested that HCPT inhibited ESCC growth, arrested cell cycle progression, and induced apoptosis both in vitro and in vivo via decreasing the expression and activity of TOP I enzyme.
Collapse
Affiliation(s)
- Mengqiu Song
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; (M.S.); (S.Y.); (R.Z.); (K.L.)
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
| | - Shuying Yin
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; (M.S.); (S.Y.); (R.Z.); (K.L.)
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
| | - Ran Zhao
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; (M.S.); (S.Y.); (R.Z.); (K.L.)
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
| | - Kangdong Liu
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; (M.S.); (S.Y.); (R.Z.); (K.L.)
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
- The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou 450001, China
| | - Joydeb Kumar Kundu
- Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, AB T6G 2R3, Canada;
| | - Jung-Hyun Shim
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
- Department of Pharmacy, College of Pharmacy, Mokpo National University, Jeonnam 58554, Korea
| | - Mee-Hyun Lee
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; (M.S.); (S.Y.); (R.Z.); (K.L.)
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
- The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou 450001, China
- Correspondence: or (M.-H.L.); (Z.D.); Tel.: +86-371-6558-7008 (M.-H.L.); +86-371-6558-7008 (Z.D.); Fax: +86-371-6558-7670 (M.-H.L.); +86-371-6558-7670 (Z.D.)
| | - Zigang Dong
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; (M.S.); (S.Y.); (R.Z.); (K.L.)
- China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou 450008, China;
- Correspondence: or (M.-H.L.); (Z.D.); Tel.: +86-371-6558-7008 (M.-H.L.); +86-371-6558-7008 (Z.D.); Fax: +86-371-6558-7670 (M.-H.L.); +86-371-6558-7670 (Z.D.)
| |
Collapse
|
4
|
Naro Y, Ankenbruck N, Thomas M, Tivon Y, Connelly CM, Gardner L, Deiters A. Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. J Med Chem 2018; 61:5900-5909. [PMID: 29993250 DOI: 10.1021/acs.jmedchem.7b01891] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a >10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.
Collapse
Affiliation(s)
- Yuta Naro
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| | - Nicholas Ankenbruck
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| | - Meryl Thomas
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| | - Yaniv Tivon
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| | - Colleen M Connelly
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| | - Laura Gardner
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| | - Alexander Deiters
- Department of Chemistry , University of Pittsburgh , Pittsburgh , Pennsylvania 15260 , United States
| |
Collapse
|
5
|
Czubaty A, Piekiełko-Witkowska A. Protein kinases that phosphorylate splicing factors: Roles in cancer development, progression and possible therapeutic options. Int J Biochem Cell Biol 2017; 91:102-115. [PMID: 28552434 DOI: 10.1016/j.biocel.2017.05.024] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 05/16/2017] [Accepted: 05/18/2017] [Indexed: 11/30/2022]
Abstract
Disturbed alternative splicing is a common feature of human tumors. Splicing factors that control alternative splicing are phosphorylated by multiple kinases, including these that specifically add phosphoryl groups to serine-arginine rich proteins (e.g. SR-protein kinases, cdc2-like kinases, topoisomerase 1), and protein kinases that govern key cellular signaling pathways (i.e. AKT). Phosphorylation of splicing factors regulates their subcellular localization and interactions with target transcripts and protein partners, and thus significantly contributes the final result of splicing reactions. In this review we aim to summarize the current knowledge on the role of splicing kinases in cancer. Published studies and recently released data of The Cancer Genome Atlas demonstrate that expressions and activities of splicing kinases are commonly disturbed in cancers. Aberrant functioning of splicing kinases results in changed alternative splicing of tumor suppressors (e.g. p53) and regulators of cell signaling (e.g. MAPKs), apoptosis (e.g. MCL), and angiogenesis (VEGF). Splicing kinases act in complicated regulatory networks in which they mutually affect each other's activity to provide tight control of cellular signaling. Dysregulation of these regulatory networks contributes to oncogenic transformation, uncontrolled proliferation, enhanced migration and invasion. Furthermore, the activities of splicing kinases significantly contribute to cellular responses to genotoxic stress. In conclusion, published data provide strong evidence that splicing kinases emerge as important regulators of key processes governing malignant transformation, progression, and response to therapeutic treatments, suggesting their potential as clinically relevant targets.
Collapse
Affiliation(s)
- Alicja Czubaty
- Department of Molecular Biology, Faculty of Biology, University of Warsaw, ul. Miecznikowa 1, 02-096 Warsaw, Poland
| | - Agnieszka Piekiełko-Witkowska
- Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, ul. Marymoncka 99/103, 01-813 Warsaw, Poland.
| |
Collapse
|
6
|
Stenvang J, Kümler I, Nygård SB, Smith DH, Nielsen D, Brünner N, Moreira JMA. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol 2013; 3:313. [PMID: 24400218 PMCID: PMC3872326 DOI: 10.3389/fonc.2013.00313] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2013] [Accepted: 12/10/2013] [Indexed: 12/29/2022] Open
Abstract
Cancer is a leading cause of mortality worldwide and matters are only set to worsen as its incidence continues to rise. Traditional approaches to combat cancer include improved prevention, early diagnosis, optimized surgery, development of novel drugs, and honing regimens of existing anti-cancer drugs. Although discovery and development of novel and effective anti-cancer drugs is a major research area, it is well known that oncology drug development is a lengthy process, extremely costly and with high attrition rates. Furthermore, those drugs that do make it through the drug development mill are often quite expensive, laden with severe side-effects and unfortunately, to date, have only demonstrated minimal increases in overall survival. Therefore, a strong interest has emerged to identify approved non-cancer drugs that possess anti-cancer activity, thus shortcutting the development process. This research strategy is commonly known as drug repurposing or drug repositioning and provides a faster path to the clinics. We have developed and implemented a modification of the standard drug repurposing strategy that we review here; rather than investigating target-promiscuous non-cancer drugs for possible anti-cancer activity, we focus on the discovery of novel cancer indications for already approved chemotherapeutic anti-cancer drugs. Clinical implementation of this strategy is normally commenced at clinical phase II trials and includes pre-treated patients. As the response rates to any non-standard chemotherapeutic drug will be relatively low in such a patient cohort it is a pre-requisite that such testing is based on predictive biomarkers. This review describes our strategy of biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy, taking the repurposing of topoisomerase I (Top1) inhibitors and Top1 as a potential predictive biomarker as case in point.
Collapse
Affiliation(s)
- Jan Stenvang
- Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Section for Molecular Disease Biology and Sino-Danish Breast Cancer Research Centre, University of Copenhagen , Copenhagen , Denmark ; Danish Centre for Translational Breast Cancer Research , Copenhagen , Denmark
| | - Iben Kümler
- Department of Oncology, Center for Cancer Research, Herlev Hospital, University of Copenhagen , Copenhagen , Denmark
| | - Sune Boris Nygård
- Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Section for Molecular Disease Biology and Sino-Danish Breast Cancer Research Centre, University of Copenhagen , Copenhagen , Denmark
| | - David Hersi Smith
- Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Section for Molecular Disease Biology and Sino-Danish Breast Cancer Research Centre, University of Copenhagen , Copenhagen , Denmark ; DAKO A/S , Glostrup , Denmark
| | - Dorte Nielsen
- Department of Oncology, Center for Cancer Research, Herlev Hospital, University of Copenhagen , Copenhagen , Denmark
| | - Nils Brünner
- Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Section for Molecular Disease Biology and Sino-Danish Breast Cancer Research Centre, University of Copenhagen , Copenhagen , Denmark ; Danish Centre for Translational Breast Cancer Research , Copenhagen , Denmark
| | - José M A Moreira
- Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Section for Molecular Disease Biology and Sino-Danish Breast Cancer Research Centre, University of Copenhagen , Copenhagen , Denmark ; Danish Centre for Translational Breast Cancer Research , Copenhagen , Denmark
| |
Collapse
|
7
|
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today 2011; 41:1196-9. [DOI: 10.1007/s00595-011-4546-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2010] [Accepted: 03/01/2011] [Indexed: 10/17/2022]
|
8
|
Tsavaris N, Lazaris A, Kosmas C, Gouveris P, Kavantzas N, Kopterides P, Papathomas T, Arapogiannis G, Zorzos H, Kyriakou V, Patsouris E. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2008; 64:391-8. [PMID: 19083133 PMCID: PMC2688619 DOI: 10.1007/s00280-008-0886-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2008] [Accepted: 11/21/2008] [Indexed: 11/26/2022]
Abstract
Purpose Human DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and outcome after chemotherapy in primary and relapsed colorectal cancer. Patients and methods Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study. All had undergone surgical resection of the primary tumor and received post-operatively 5-FU-based (5FU + Leucovorin, Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue was collected at the initial operation from the primary tumor and at the time of recurrence (during the second operation following chemotherapy). All tissue samples were analyzed for levels of expression of both topo-I and topo-IIa using standard three-step immunohistochemistry on paraffin sections. Results Forty patients were included. Levels of expression of topo-I and topo-II were higher in malignant cells from tumor recurrences compared to primary tumors (P = 0.0001 for both). There was a statistically significant positive relationship between patients age and levels of topo-I (P = 0.011) and topo-II (P = 0.011) expression. Conclusions The study results reported here underscore the role of topoisomerase expression in colorectal cancer and suggest a potential role in tumor recurrence.
Collapse
Affiliation(s)
- Nicolas Tsavaris
- Medical Oncology Unit, Department of Pathophysiology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece
| | - Andreas Lazaris
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Christos Kosmas
- Second Department of Medical Oncology, “Metaxa” Cancer Hospital, Piraeus, Greece
| | - Panagiotis Gouveris
- Medical Oncology Unit, Department of Pathophysiology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece
| | - Nikolaos Kavantzas
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Petros Kopterides
- Medical Oncology Unit, Department of Pathophysiology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece
| | - Thomas Papathomas
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - George Arapogiannis
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Haralambos Zorzos
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Vassiliki Kyriakou
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Efstathios Patsouris
- First Department of Pathology, Medical School, “Laikon” University General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
9
|
Gouveris P, Lazaris AC, Papathomas TG, Nonni A, Kyriakou V, Delladetsima J, Patsouris ES, Tsavaris N. Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. J Cancer Res Clin Oncol 2007; 133:1011-5. [PMID: 17605046 DOI: 10.1007/s00432-007-0253-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2006] [Accepted: 06/04/2007] [Indexed: 10/23/2022]
Abstract
PURPOSE Our aim was to investigate whether chemotherapy with 5-FU induces an alteration in the levels of topoisomerase I (topo I) in colorectal neoplastic tissues METHODS Twenty-five colorectal cancer patients were included in our study; these had undergone surgical resection of the primary tumor, received post-operatively 5-FU-based adjuvant chemotherapy and then suffered from recurrences. In a standard three-step immunohistochemical procedure, a monoclonal antibody to topo I was applied in both specimens from each patient (one from the primary location and a second one from the recurrence). Statistical analysis was subsequently performed. RESULTS Malignant cells from the recurrences displayed a statistical significant increase, concerning the levels of topoisomerase I, by comparison with the primary tumors (P=0.01). The increase in topo I levels did not demonstrate significant correlations with Duke's stage (Fisher's Exact Test P value=0.496), differentiation grade (P value=0.661), localization (P value=0.072), patient sex (P value=0.434), nor with relapse free interval (P value=0.493). There was a statistically significant relationship between the age of patients and increase in topo I levels (P=0.011). CONCLUSIONS Topo I expression may be part of the malignant cells' phenotype in recurrent colorectal carcinomas, suggesting a potential role for Topo I in the acquisition of a metastatic phenotype. The increase of topo I immunohistochemical status is likely to be attributed to 5-FU and given the fact that high levels of topo I correlate with sensitivity to camptothecin, advanced colorectal cancer patients seem to benefit from topo I targeted anticancer drug therapy.
Collapse
Affiliation(s)
- P Gouveris
- Medical Oncology Unit, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, Liu L. Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase IIα. Clin Cancer Res 2007; 13:1532-9. [PMID: 17332299 DOI: 10.1158/1078-0432.ccr-06-1595] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Methoxyamine has been shown to potentiate the cytotoxic effect of temozolomide both in vitro and in human tumor xenograft models. We postulate that the enhanced cytotoxicity is mediated by methoxyamine-bound apurininc/pyrimidinic (MX-AP) site, a key lesion formed by the combination of temozolomide and methoxyamine. When located within topoisomerase IIalpha (topo II) cleavage sites in DNA, MX-AP sites act as dual lethal targets, not only functionally disrupting the base excision repair (BER) pathway but also potentially poisoning topo II. EXPERIMENTAL DESIGN Using oligonucleotide substrates, in which a position-specific MX-AP site is located within topo II cleavage sites, we examined the effect of MX-AP site on both AP endonuclease- and topo II-mediated DNA cleavage in vitro. RESULTS MX-AP sites were refractory to the catalytic activity of AP endonuclease, indicating their ability to block BER. However, they were cleaved by either purified topo II or nuclear extracts from tumor cells expressing high levels of topo II, suggesting that MX-AP sites stimulate topo II-mediated DNA cleavages. In cells, treatment with temozolomide and methoxyamine increased the expression of topo II and enriched the formation of gammaH2AX foci, which were colocalized with up-regulated topo II, confirming that DNA double-strand breaks marked by gammaH2AX foci are associated with topo II in cells. CONCLUSIONS Our findings identify a molecular mechanism of cell death whereby MX-AP sites that cumulated in cells due to resistance to BER potentially convert topo II into biotoxins, resulting in enzyme-mediated DNA scission and cell death.
Collapse
Affiliation(s)
- Ling Yan
- Department of Medicine, Division of Hematology/Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 2002; 33:1114-9. [PMID: 12454816 DOI: 10.1053/hupa.2002.129202] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Topoisomerase I (topo I) is an important target for the treatment of malignant disease, especially colorectal cancer. Because there is little information on the expression of topo I in colorectal tumors, this study evaluated and characterized topo I protein expression in primary colorectal cancer and lymph node metastases and studied the association between topo I protein expression and clinicopathologic data, p53 status, and proliferating cell nuclear antigen (PCNA) status. Immunohistochemistry assay was performed for topo I protein expression in 249 primary human colorectal cancer and 42 paired lymph node metastasis samples. Topo I expression was described as the percentage of cells staining positive for topo I, along with the intensity and localization of the staining. Clinicopathologic data (sex, age, Dukes' stage, differentiation grade, survival status), p53 status, and PCNA status were statistically analyzed for association with topo I protein expression. Topo I expression in paired primary lymph node metastases were studied for concordance. Topo I protein expression was detected in 127 (51%) samples, including 24.4% with >50% positive tumor cells. The majority had nuclear (70.1%) or nuclear and cytoplasmic staining (17.3%). A higher percentage of cells expressing topo I in primary colorectal cancer was significantly associated with advanced age (P =.040). Patients with rectal cancer had greater topo I expression than those with colon tumors (P =.029). No significant correlation was found between topo I protein expression and sex, Dukes' stage, differentiation grade, survival status, p53 status, and PCNA status. Concordance in topo I staining between primary and lymph node metastases was observed in 33 of 42 cases (P =.029). This suggests that the activity of topo I inhibitors will not differ across various tumor stages, pathology, and patient gender. p53 and PCNA status do not appear to influence topo I expression, and topo I has no apparent association with the acquisition of a metastatic phenotype. Topo I expression now needs to be evaluated in patients undergoing topo I-inhibitor therapy, to better define the role of this protein as a predictive marker.
Collapse
Affiliation(s)
- Attasit Boonsong
- Department of Medicine & Therapeutics and Pathology, University of Aberdeen Institute of Medical Sciences, Aberdeen, Scotland, UK
| | | | | | | | | | | |
Collapse
|
12
|
Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RTD. DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer 2002; 87:624-9. [PMID: 12237772 PMCID: PMC2364243 DOI: 10.1038/sj.bjc.6600472] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2002] [Revised: 05/21/2002] [Accepted: 05/23/2002] [Indexed: 12/02/2022] Open
Abstract
A small number of testicular germ cell tumours are refractory to current chemotherapy regimens. DNA topoisomerase I is the target for several new drugs and a potential candidate treatment for chemorefractory germ cell tumours. DNA topoisomerase II alpha is the target for etoposide, which is currently used regularly in germ cell tumour treatment. The expression of DNA topoisomerase I and II alpha were therefore assessed immunohistochemically in a range of testicular tumours, especially those with persistent malignant elements on retroperitoneal lymph node dissection. Pre-chemotherapy orchidectomy specimens were matched with post-chemotherapy retroperitoneal lymph node dissections to examine changes in expression. There was considerable variation in the expression of topoisomerase I in different tumour types. Both yolk sac tumours and teratoma, mature showed universal expression of topoisomerase I, while 38% of seminomas and 30% of embryonal carcinomas were positive. Strong topoisomerase II alpha expression was found in embryonal carcinoma. There was a negative correlation between topoisomerase I and II alpha expression (P=0.004) and downregulation of topoisomerase II alpha after chemotherapy (P=0.02). Topoisomerase I expression appears to increase in those cases with residual teratoma, mature, but is largely unchanged in those cases remaining as embryonal carcinoma. These results suggest that topoisomerase I inhibitors may be useful in chemorefractory germ cell tumours, especially yolk sac tumours and where there are unresectable residual teratoma, mature deposits.
Collapse
Affiliation(s)
- D M Berney
- Department of Histopathology and Morbid Anatomy, St Bartholomew's Hospital, Queen Mary's School of Medicine and Dentistry, London EC1 7BE, UK.
| | | | | | | | | |
Collapse
|